[Radiotherapeutic effect of naphthidon-3H in combined action on Harding-Passey melanoma].
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001345:Autoradiography; D003520:Cyclophosphamide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006651:Histocytochemistry; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007958:Leukocyte Count; D008545:Melanoma / Q000032:analysis / Q000188:drug therapy* / Q000532:radiotherapy; D051379:Mice; D009374:Neoplasms, Experimental / Q000032:analysis / Q000188:drug therapy / Q000532:radiotherapy; D009848:Olivomycins / Q000627:therapeutic use; D009943:Organophosphorus Compounds / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D013997:Time Factors; D014316:Tritium; D014812:Vitamin K / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D009943:Organophosphorus Compounds; D011838:Radiation-Sensitizing Agents; D014316:Tritium; D014812:Vitamin K; D009848:Olivomycins; D003520:Cyclophosphamide; D011239:Prednisolone
Radioterapevticheskiĭ éffekt naftidona-3H pri kombinirovannom vozdeĭstvii na melanomu Garding-Passi